1文献来源Finn RS,Qin S,Ikeda M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.2证据水平1b。3背景索拉非尼与仑伐替尼作为不可切除肝癌的一线系统治疗...1文献来源Finn RS,Qin S,Ikeda M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.2证据水平1b。3背景索拉非尼与仑伐替尼作为不可切除肝癌的一线系统治疗具有明显的副作用。既往文献表明,程序性死亡受体1(programmed cell death 1,PD-1)抑制剂并未明显提高肝癌患者总生存期(overall survival,OS)。展开更多
1文献来源Kudo M,Ueshima K,Ikeda M,et al. Randomised,multicentre prospective trial of transarterial-chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS ...1文献来源Kudo M,Ueshima K,Ikeda M,et al. Randomised,multicentre prospective trial of transarterial-chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut,2020,69(8):1492-1501.展开更多
1文献来源Chen J,Lu L,Wen T,et al. 2021 ESMO 945P-Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE):Updated results from a multi-center p...1文献来源Chen J,Lu L,Wen T,et al. 2021 ESMO 945P-Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE):Updated results from a multi-center prospective cohort study[J]. Ann Oncol,2021,32(5S):S818-S828.展开更多
文摘1文献来源Finn RS,Qin S,Ikeda M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.2证据水平1b。3背景索拉非尼与仑伐替尼作为不可切除肝癌的一线系统治疗具有明显的副作用。既往文献表明,程序性死亡受体1(programmed cell death 1,PD-1)抑制剂并未明显提高肝癌患者总生存期(overall survival,OS)。
文摘1文献来源Kudo M,Ueshima K,Ikeda M,et al. Randomised,multicentre prospective trial of transarterial-chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut,2020,69(8):1492-1501.
文摘1文献来源Chen J,Lu L,Wen T,et al. 2021 ESMO 945P-Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE):Updated results from a multi-center prospective cohort study[J]. Ann Oncol,2021,32(5S):S818-S828.
